Sign Out
In patients with known hypersensitivity to posaconazole or any component of the product.
Although not studied in vitro or in vivo, coadministration of the CYP3A4 substrates terfenadine, astemizole, cisapride, pimozide, or quinidine with posaconazole are contraindicated since increased plasma concentrations of these drugs can lead to QT prolongation and rare occurrences of torsade de pointes.
Coadministration with the HMG-CoA reductase inhibitors that are primarily metabolized through CYP3A4 is contraindicated since increased plasma concentration of these drugs can lead to rhabdomyolysis.
Although not studied in vitro or in vivo, posaconazole may increase the plasma concentrations of ergot alkaloids which may lead to ergotism. Coadministration of posaconazole and ergot alkaloids is contraindicated.
